Phaseline

Targets › IGHM

IGHM (Immunoglobulin heavy constant mu): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Mar 2027.

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. (UniProt, P01871)

Open in Phaseline: the race on IGHM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RAPT Therapeutics, Inc., a member of the GSK plc group of companiesRPT904
anti-IgE monoclonal antibody
IGHMPhase 2Immune System DiseasesMar 2027
Lycia TherapeuticsLCA-0061
Antibody-based therapeutic designed to selectively bind and rapidly clear immunoglobulin E
IGHMPhase 1Atopic DiseaseApr 2028

Conditions

Immune System Diseases (1) Atopic Disease (1)

Modalities

antibody (1), small molecule (1)

Companies

RAPT Therapeutics, Inc., a member of the GSK plc group of companies (1) Lycia Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.